<DOC>
	<DOCNO>NCT01689285</DOCNO>
	<brief_summary>A new paediatric formulation ( oral liquid ) develop flexible accurate dose valacyclovir child . To establish bioavailability new formulation , healthy volunteer expose new formulation valacyclovir tablet . The concentration valacyclovir blood exposure oral liquid measure compare tablet .</brief_summary>
	<brief_title>Bioequivalence Study Healthy Volunteers New Paediatric Formulation Valacyclovir</brief_title>
	<detailed_description>Bioequivalence new valcyclovir formulation test accord EMA guideline bioequivalence .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Subject least 18 old 55 year age screening . Subject smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior first dose Subject Quetelet Index ( Body Mass Index ) 18 30 kg/m2 , extremes include . Subject sign Informed Consent Form prior screen evaluation . Subject good ageappropriate health condition establish medical history , physical examination , electrocardiography , result biochemistry , haematology urinalysis test within 4 week prior first dose . Results biochemistry , haematology urinalysis test within laboratory 's reference range ( see Appendix A ) . If laboratory result within reference range , subject include condition investigator judge deviation clinically relevant . This clearly record . Subject normal blood pressure pulse rate , accord investigator 's judgement . Female subject either childbearing potential , defined postmenopausal least 1 year childbearing potential adequate contraception ( e.g . hysterectomy , bilateral tubal ligation , ( nonhormonal ) intrauterine device , total abstinence , double barrier method , vasectomized partner ) . Documented history sensitivity/idiosyncrasy medicinal product excipients . Positive HIV , hepatitis B C test . Therapy drug ( two week precede dose ) , except acetaminophen . Relevant history presence pulmonary disorder ( especially COPD ) , cardiovascular disorder , neurological disorder ( especially seizures migraine ) , gastrointestinal disorder , renal hepatic disorder , hormonal disorder ( especially diabetes mellitus ) , coagulation disorder . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . History current abuse drug , alcohol solvent . Inability understand nature extent trial procedure require . Participation drug trial within 60 day prior first dose . Donation blood within 60 day prior first dose . Febrile illness within 3 day first dose . Pregnant female ( confirm HCG test perform less 4 week first dose ) breastfeed female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>valacyclovir</keyword>
	<keyword>paediatric formulation</keyword>
</DOC>